From: Bleeding disorders in implant dentistry: a narrative review and a treatment guide
Type 1 | Quantitative deficiency of VWF | 80% of patients | |
Type 2 | A | Qualitative deficiency of VWF with reduced binding ability of VWF to platelets and collagen and reduced high molecular monomers | 15–20% of patients |
B | Qualitative deficiency of VWF with increased affinity for platelet-derived GPIb-receptor and reduced high molecular monomers | ||
M | Reduced affinity to platelets with a functional defect in primary hemostasis and decreased ratio of ristocetin cofactor activity to VWF antigen | ||
N | Reduced affinity for factor VIII | ||
Type 3 | Complete absence or severe reduction of VWF | 0.5–1.5% of patients |